Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine Plus Cisplatin in Muscle-invasive Bladder Cancer With Bladder Preservation for DDR Altered Tumors
NCT03609216Phase 2Active, not recruiting
- Sponsor
- Cancer and Leukemia Group B
- Start
- Dec 2018
- Primary completion
- Oct 2028
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine and Cisplatin micelle injection (HA132) in bladder urothelial carcinoma (2 arms), sponsored by Cancer and Leukemia Group B. Primary endpoint: Event-Free Survival at 3 years. Started Dec 2018; status: active, not recruiting.
02
Drugs
gemcitabineCisplatin micelle injection (HA132)
03
Conditions
bladder urothelial carcinoma
Beyond the preview
Go deeper on NCT03609216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03609216.